Orforglipron vs Follistatin 344
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
OrforglipronAnabolic & IGF
Follistatin 344- Summary
- Orforglipron is an oral, once-daily small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike injectable GLP-1 peptides, it is a non-peptide compound absorbed orally without food restrictions, representing a major convenience advancement. Phase 2 trials showed up to 9.4% weight loss at 36 weeks, and Phase 3 trials (ATTAIN program) are ongoing for obesity and type 2 diabetes.
- Follistatin 344 is a recombinant form of the endogenous follistatin protein. It inhibits myostatin and activin — the primary negative regulators of muscle growth — potentially removing the genetic ceiling on muscle development. It is one of the most theoretically powerful anabolic compounds but is experimental with limited human data.
- Half-Life
- ~12 hours (once-daily oral dosing)
- ~24–36 hours
- Admin Route
- Oral
- SubQ, IM
- Research
- —
- —
- Typical Dose
- 12 mg → 24 mg → 36 mg → 45 mg
- 100 mcg
- Frequency
- Once daily
- Once daily
- Key Benefits
- Oral pill — no injections required
- Once-daily dosing without food restrictions (unlike oral semaglutide)
- Up to 9.4% body weight reduction in Phase 2 at 36 weeks
- Significant HbA1c reduction in type 2 diabetes trials
- Small-molecule stability — no cold chain requirements
- Broadens access for injection-averse patients
- Potential class-defining convenience advantage over injectable GLP-1s
- Inhibits myostatin — removes muscle growth ceiling
- Significant increases in muscle mass and strength
- Reduces fat mass
- Promotes bone density
- May stimulate hair follicle cycling
- Anti-fibrotic effects in muscle tissue
- Synergistic with IGF-1 and other anabolic peptides
- Side Effects
- Nausea (most common, dose-dependent)
- Vomiting
- Diarrhea
- Decreased appetite
- +2 more
- Muscle soreness (from rapid hypertrophy)
- Potential reproductive effects (activin inhibition)
- Unknown long-term safety profile
- Possible esophageal effects at high doses (animal data)
- Stacks With
- —
- —